Key result
Percutaneous device closure of atrial septal defects is associated with late complications such as cardiac erosion, thromboembolism, and infective endocarditis that carry significant morbidity.
Why the study?
What are the long-term complications associated with percutaneous device closure of atrial septal defects?
What are the long-term complications associated with percutaneous device closure of atrial septal defects?
While short-term outcomes of percutaneous ASD closure are noninferior to surgery, clinicians must remain vigilant for significant late complications such as cardiac erosion and thromboembolism.
Percutaneous device closure of atrial septal defects (ASDs) was introduced in the late 1990s as a feasible alternative to surgical repair.1 Since then, several studies have shown that short-term outcomes and complication rates after percutaneous ASD closure are noninferior to those after surgery.2,3 However, an important consideration with percutaneous ASD closure is the prevalence of late complications that have come to light after its widespread adoption. Some of these, including cardiac erosion, thromboembolism, and infective endocarditis, carry significant morbidity and mortality.
No takes yet. Share an insight, caveat, or question.
Prabhu et al. (2021) conducted an editorial in Atrial septal defects (ASDs). Percutaneous device closure vs. Surgical repair was evaluated. Percutaneous device closure of atrial septal defects is associated with late complications such as cardiac erosion, thromboembolism, and infective endocarditis that carry significant morbidity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: